AstraZeneca to transfer rights to Eklira, Duaklir
1 November 2021 07:00 GMT AstraZeneca to transfer global rights for Eklira and Duaklir to Covis Pharma Agreement sharpens AstraZeneca’s focus on priority medicinesin Respiratory & Immunology portfolio AstraZeneca has agreed to transfer its global rights to Eklira (aclidinium bromide), known as Tudorza in the US, and Duaklir (aclidinium bromide/formoterol) to Covis Pharma Group (Covis Pharma). Both medicines are delivered via the Genuair device and used for the treatment of patients with chronic obstructive pulmonary disease (COPD). The agreement will ensure continued